You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 102 No. 4, OCTOBER 1958 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Phenethyl-, Amyl-, and Isoamylbiguanide in the Treatment of Diabetes Mellitus

WILLIAM D. ODELL, M.D.; DONALD C. TANNER, M.D.; DONALD F. STEINER, M.D.; ROBERT H. WILLIAMS, M.D.

AMA Arch Intern Med. 1958;102(4):520-526.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In 1926, Frank et al.1 synthesized Synthalin A (decamethylenediguanidine) and showed that oral administration of the drug lowered the blood sugar remarkably in partially depancreatized animals and in human diabetics. A few diabetic patients were treated with Snythalin A, but it was subsequently proved to be quite toxic even in small doses,2,3 producing histological changes in the liver and kidney after one or two days, and all clinical use of the drug was discontinued. However, other compounds containing this guanidine group (Fig. 1) were not so toxic. Indeed, it is known that normal body constituents such as creatine and arginine contain the guanidine group. Also, Paludrine [N1-(p-chlorophenyl)-N5-isopropylbiguanide] has a mild hypoglycemic action, and it has been used successfully for several years in the treatment of malaria.12,13

Recently, in a search for hypoglycemic compounds, Ungar4 found that phenethylformamidinyliminourea (also referred to as phenethyldiguanide, or DBI, but preferably called phenethylbiguanide, or PEBG) . . . [Full Text PDF of this Article]


Author Affiliations

Seattle

Department of Medicine, University of Washington School of Medicine.


Footnotes

Submitted for publication June 3, 1958.

Dr. Emily Fergus cooperated in and referred patients for use in this study.

All biguanide compounds used were supplied by the U. S. Vitamin Corporation.

This investigation was supported in large part by research grants from the National Institute of Arthritis and Metabolic Diseases, Public Health Service.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1958 American Medical Association. All Rights Reserved.